Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AbCellera Biologics stock

Own AbCellera Biologics stock in just a few minutes.

Our pick for beginner investors: Robinhood

Robinhood logo
  • $0 commissions
  • Download the app or trade online
  • Start trading right away with instant deposits
Go to site

AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.

How to buy shares in AbCellera Biologics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ABCL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

AbCellera Biologics share price

Use our graph to track the performance of ABCL stocks over time.

AbCellera Biologics shares at a glance

Information last updated 2021-03-09.
52-week range$26.16 - $71.91
50-day moving average $43.81
200-day moving average $43.75
Wall St. target price$55.80
PE ratio 3270.405
Dividend yield N/A (0%)
Earnings per share (TTM) $0.02

Buy AbCellera Biologics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AbCellera Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is AbCellera Biologics under- or over-valued?

Valuing AbCellera Biologics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbCellera Biologics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AbCellera Biologics's P/E ratio

AbCellera Biologics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3270x. In other words, AbCellera Biologics shares trade at around 3270x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, AbCellera Biologics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

AbCellera Biologics financials

Revenue TTM $28.4 million
Gross profit TTM $1.5 million
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0.98%
Book value N/A
Market capitalisation $8.2 billion

TTM: trailing 12 months

Shorting AbCellera Biologics shares

There are currently 2.2 million AbCellera Biologics shares held short by investors – that's known as AbCellera Biologics's "short interest". This figure is 23.1% down from 2.9 million last month.

There are a few different ways that this level of interest in shorting AbCellera Biologics shares can be evaluated.

AbCellera Biologics's "short interest ratio" (SIR)

AbCellera Biologics's "short interest ratio" (SIR) is the quantity of AbCellera Biologics shares currently shorted divided by the average quantity of AbCellera Biologics shares traded daily (recently around 671808.10810811). AbCellera Biologics's SIR currently stands at 3.33. In other words for every 100,000 AbCellera Biologics shares traded daily on the market, roughly 3330 shares are currently held short.

To gain some more context, you can compare AbCellera Biologics's short interest ratio against those of similar companies.

However AbCellera Biologics's short interest can also be evaluated against the total number of AbCellera Biologics shares, or, against the total number of tradable AbCellera Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AbCellera Biologics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 AbCellera Biologics shares in existence, roughly 10 shares are currently held short) or 0.0186% of the tradable shares (for every 100,000 tradable AbCellera Biologics shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AbCellera Biologics.

Find out more about how you can short AbCellera Biologics stock.

AbCellera Biologics share dividends

We're not expecting AbCellera Biologics to pay a dividend over the next 12 months.

AbCellera Biologics overview

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site